Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group
We evaluated the efficacy and safety of sequential therapy with trastuzumab monotherapy (H-mono) followed by H plus docetaxel (D) after disease progression (H → H + D) versus combination therapy with H + D as first-line therapy. Patients with human epidermal growth factor receptor type 2 (HER2)-positive metastatic breast cancer (MBC) and left ventricular ejection fraction >50% were randomly assigned to either (a) H → H + D [H, once weekly 2 mg/kg (loading dose, 4 mg/kg); D, once every 3 weeks 60 mg/m2] or (b) H + D. Primary endpoints were progression-free survival (PFS) for the H-mono stage of the H → H + D group and H + D group and overall survival (OS) for both groups. Secondary endpoints were overall response rate, time to treatment failure, second PFS and safety. The planned number of patients was 160 patients in total. Of 112 patients enrolled, 107 were eligible. After 112 patients were enrolled, the Independent Data Monitoring Committee recommended stopping enrollment because PFS and OS were greater in the H + D group than the H → H + D group. Median PFS was 445 days in the H + D group versus 114 days for H-mono in the H → H + D group [hazard ratio (HR), 4.24; P < 0.01]. OS was significantly longer in the H + D group (HR, 2.72; P = 0.04). H + D therapy is significantly superior to H → H + D therapy as first-line therapy in patients with HER2-positive MBC, especially in terms of OS.
KeywordsTrastuzumab Docetaxel Combination therapy Metastatic breast cancer First-line therapy
We thank the patients who participated in this trial and their families; the medical, nursing, and research staff at the institutions; the independent data and safety monitoring committee; the monitors, data managers, statisticians, and programmers at Chugai Pharmaceutical and EPS. This study was sponsored and funded by Chugai Pharmaceutical.
- 3.NCCN Clinical Practice Guidelines in Oncology version 1 (2009) Breast cancer. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf
- 5.Marty M, Cognetti F, Maraninchi D et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23:4265–4274CrossRefPubMedGoogle Scholar
- 7.Fountzilas G, Razis E, Tsavdaridis D et al (2003) Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the Hellenic cooperative oncology group. Clin Breast Cancer 4:120–125CrossRefPubMedGoogle Scholar
- 9.Antoine EC, Extra JM, Vincent-Salomon A et al (2007) Multiple lines of trastuzumab provide a survival benefit for women with metastatic breast cancer: results from the Hermine cohort study [abstract]. Eur J Cancer 5(suppl):213 Abstract 2099Google Scholar
- 10.Mackey J, Gelmon KA, Verma S et al (2002) Continued use of Herceptin after disease progression in women with HER2-positive (HER2+) metastatic breast cancer (MBC): results from a retrospective analysis of 105 cases [abstract]. J Clin Oncol 21:52a Abstract 207Google Scholar
- 11.Von Minckwitz G, Zielinski C, Maarteense E et al (2008) Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: the TBP phase III study (GBG 26/BIG 3–05) [abstract]. J Clin Oncol 26(suppl):47s Abstract 1025Google Scholar
- 12.O’Shaughnessy J, Blackwell KL, Burstein H et al (2008) A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy [abstract]. J Clin Oncol 26(suppl):44s Abstract 1015Google Scholar
- 13.Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National cancer institute of the United States, National cancer institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMedGoogle Scholar
- 14.Bontenbal M, Seynaeve C, Stouthard J et al (2008) Randomized study comparing efficacy/toxicity of monotherapy trastuzumab followed by monotherapy docetaxel at progression, and combination trastuzumab/docetaxel as first-line chemotherapy in HER2-neu positive, metastatic breast cancer (MBC) (HERTAX study) [abstract]. J Clin Oncol 26(suppl):44s Abstract 1014Google Scholar
- 16.Tripathy D, Slamon D, Leyland-Jones B et al (2000) Treatment beyond progression in the Herceptin pivotal combination chemotherapy trial [abstract]. Breast Cancer Res Treat 64:32 Abstract 25Google Scholar